LEIDEN, The Netherlands, March 24 /PRNewswire-FirstCall/ -- Pharming Group N.V. (“Pharming” or “the Company”), (Euronext:PHARM), (PHAR.AS), announced today that the Company has been included in the Next 150 Index on the stock exchange of Euronext N.V. (Euronext).
The Next 150 Index is comprised of mid to large capitalisation stocks on the Euronext exchange. The index consists of the 150 next largest stocks following the Euronext 100 index and includes stocks from the Amsterdam, Brussels, Lisbon and Paris exchanges of Euronext.
“Pharming is pleased to be included in the Next 150 Index as it highlights the financial performance and progress with its lead product in Phase III clinical trials,” said Dr. Francis Pinto, CEO of Pharming. “The inclusion of Pharming in the Next 150 Index will further increase awareness of our achievements and encourage participation of institutional investors.”
Pharming will be included in the Euronext Next 150 Index as of April 1st, 2005. For further information on the Euronext Next 150 Index, please visit http://www.euronext.com/.
Background on Pharming Group N.V.
Pharming Group N.V. is developing innovative protein therapeutics for unmet medical needs. The Company’s products include potential treatments for genetic disorders, specialty products for surgical indications, and intermediates for various applications. Pharming’s lead product (recombinant human C1 inhibitor) for hereditary angioedema is in Phase III of clinical development. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, as well as technology and processes for the purification and formulation of these products. Additional information is available on the Pharming website, http://www.pharming.com/.
This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.
Pharming Group N.V.
CONTACT: Contact: Samir Singh, Pharming Group N.V., T: +1-908-720-6224,T: + 31-(0)71-524-7431